Cargando…

Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products

OBJECTIVE: We sought to establish the performance of cell-bound complement activation products (CB-CAPs) as a diagnostic tool to distinguish primary fibromyalgia (FM) from systemic lupus erythematosus (SLE). METHODS: A total of 75 SLE and 75 primary FM adult subjects who fulfilled appropriate classi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wallace, Daniel J, Silverman, Stuart L, Conklin, John, Barken, Derren, Dervieux, Thierry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Biomarker Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746498/ https://www.ncbi.nlm.nih.gov/pubmed/26870391 http://dx.doi.org/10.1136/lupus-2015-000127

Ejemplares similares

Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus
por: Buyon, Jill, et al.
Publicado: (2016)

Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements
por: Putterman, Chaim, et al.
Publicado: (2014)

Erythrocyte complement receptor 1 (ECR1) and erythrocyte-bound C4d (EC4d) in the prediction of poor pregnancy outcomes in systemic lupus erythematosus (SLE)
por: Conklin, John, et al.
Publicado: (2022)

Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE
por: Petri, Michelle A, et al.
Publicado: (2019)

A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus
por: Alexander, Roberta Vezza, et al.
Publicado: (2021)

Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE
por: Merrill, Joan T, et al.
Publicado: (2018)

The Avise Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus
por: Mossell, James, et al.
Publicado: (2016)

Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE
por: Wallace, Daniel J, et al.
Publicado: (2019)

Evaluation of different ways to identify persistent positivity of lupus anticoagulant in systemic lupus erythematosus
por: Petri, Michelle A, et al.
Publicado: (2020)

Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus
por: Cornwell, MacIntosh Grant, et al.
Publicado: (2021)

Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2018)

Brain metabolism and autoantibody titres predict functional impairment in systemic lupus erythematosus
por: Mackay, Meggan, et al.
Publicado: (2015)

Blood-based candidate biomarkers of the presence of neuropsychiatric systemic lupus erythematosus in children
por: Brunner, Hermine I, et al.
Publicado: (2014)

Molecular signatures in systemic lupus erythematosus: distinction between disease flare and infection
por: Mackay, Meggan, et al.
Publicado: (2016)

TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus
por: Idborg, Helena, et al.
Publicado: (2018)

Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis
por: Northcott, Melissa, et al.
Publicado: (2022)

Glycosphingolipid-associated β-1,4 galactosyltransferase is elevated in patients with systemic lupus erythematosus
por: Sadras, Vignesh, et al.
Publicado: (2020)

Inflammatory markers in saliva and urine reflect disease activity in patients with systemic lupus erythematosus
por: Ruacho, Guillermo, et al.
Publicado: (2022)

Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies
por: Brunekreef, Tammo, et al.
Publicado: (2021)

Quinolinic acid, a kynurenine/tryptophan pathway metabolite, associates with impaired cognitive test performance in systemic lupus erythematosus
por: Anderson, Erik W, et al.
Publicado: (2021)

Elevation of serum anti–glucose-regulated protein 78 antibodies in neuropsychiatric systemic lupus erythematosus
por: Matsueda, Yu, et al.
Publicado: (2018)

Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2020)

Smoking associates with increased BAFF and decreased interferon-γ levels in patients with systemic lupus erythematosus
por: Raymond, Warren David, et al.
Publicado: (2021)

Differential expression of antibodies to NMDA receptor in anti-NMDA receptor encephalitis and in neuropsychiatric systemic lupus erythematosus
por: Hirohata, Shunsei, et al.
Publicado: (2019)

RNA tape sampling in cutaneous lupus erythematosus discriminates affected from unaffected and healthy volunteer skin
por: Merola, Joseph F, et al.
Publicado: (2021)

Influence of hydroxychloroquine blood levels on adhesion molecules associated with endothelial dysfunction in patients with systemic lupus erythematosus
por: Fasano, Serena, et al.
Publicado: (2022)

Lower vitamin D levels are associated with higher systemic lupus erythematosus activity, but not predictive of disease flare-up
por: Schoindre, Yoland, et al.
Publicado: (2014)

Vitamin D level in patients with systemic lupus erythematosus: its relationship to disease course and bone mineral density
por: Shevchuk, Sergii, et al.
Publicado: (2023)

Plasma levels of galectin-3-binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus
por: Nielsen, Christoffer T, et al.
Publicado: (2014)

ANA positivity and complement level in pleural fluid are potential diagnostic markers in discriminating lupus pleuritis from pleural effusion of other aetiologies
por: Chen, Der-Yuan, et al.
Publicado: (2021)

Cell-bound complement activation products associate with lupus severity in SLE
por: Arriens, Cristina, et al.
Publicado: (2020)

Can Cell Bound Complement Activation Products Predict Inherited Complement Deficiency in Systemic Lupus Erythematosus?
por: Raj, Naveen, et al.
Publicado: (2016)

Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial
por: McDonald, Stephen, et al.
Publicado: (2022)

Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus
por: Ramsey‐Goldman, Rosalind, et al.
Publicado: (2019)

Cell-bound complement activation products in SLE
por: Ramsey-Goldman, Rosalind, et al.
Publicado: (2017)

Urine proteomic insights from the belimumab in lupus nephritis trial
por: Weeding, Emma, et al.
Publicado: (2022)

sIL7R concentrations in the serum reflect disease activity in the lupus kidney
por: Lauwerys, B R, et al.
Publicado: (2014)

Serum interferon-alpha predicts in-hospital mortality in patients hospitalised with acute severe lupus
por: Yerram, Keerthi Vardhan, et al.
Publicado: (2023)

Urine TWEAK level as a biomarker for early response to treatment in active lupus nephritis: a prospective multicentre study
por: Suttichet, Thitima Benjachat, et al.
Publicado: (2019)

Similar dysregulation of lupus-associated miRNAs in peripheral blood mononuclear cells and splenic lymphocytes in MRL/lpr mice
por: Wang, Zhuang, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5s0ml1b4hvpaje2rdatv869s5p